Ultime notizie per Ascent Industries (NASDAQ:ACNT) Azioni

Ascent Industries

Ascent Industries Co is engaged in the chemical and metal industry. The group operates into two reportable segments namely the Specialty Chemicals and Tubular Products. The Tubular Products segment serves markets through pipe and tube and customers in the appliance, architectural, automotive, and commercial transportation, brewery, chemical, petrochemical, and other industries. The Specialty Chemicals segment produces specialty products for pulp and paper, coatings, adhesives, sealants, and elastomers (CASE), textile, automotive, household, and other industries. It manufactures welded pipe and tube, majorly from stainless steel, duplex, and nickel alloys. The company also produces specialty chemicals and dyes used in various end markets.

Wall Street Bull

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ACNT

Le valutazioni estreme aprono scenari inaspettati, mentre alcuni titoli ipervenduti mostrano segnali di possibile ripresa.

Titoli ipervenduti: quali aziende potrebbero sorprendere il mercato?

TROX

Scopri i 3 titoli del settore materiali con RSI basso che potrebbero offrire opportunità di acquisto oggi.

3 titoli del settore dei materiali da tenere d&#39;occhio oggi

WIIM

ZVSA

ZyVersa Therapeutics shares are trading higher after the company announced it provided regulatory and product support for an FDA-authorized emergency compassionate use of cholesterol efflux mediator VAR 200.

<a href="https://www.bloomberg.com/news/articles/2025-07-08/russia-s-oil-exports-slow-to-the-lowest-since-february?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-07-08/russia-s-oil-exports-slow-to-the-lowest-since-february?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-07-08/russia-s-oil-exports-slow-to-the-lowest-since-february?srnd=homepage-americas</a>

'Russia's Crude Shipments Slide To Lowest Since February' -Bloomberg

The current market environment reflects deep uncertainty about the direction of U.S. economic policy. Since the November election, investors have been grappling with a core ambiguity: will the new administration focus on deficit reduction and inflation control to stabilize the long end of the yield curve — or continue to rely on expansionary fiscal measures to sustain growth and support equities?
This policy indecision is playing out in real time through the S&amp;P 500 vs. TLT ratio — a proxy for equity optimism relative to long-duration bond sentiment. Stocks appear to be the clear winner for now, but the uncertainty is far from over.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="512" height="308" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08072415/unnamed-6.png" alt="" class="wp-image-15440" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08072415/unnamed-6.png 512w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08072415/unnamed-6-300x180.png 300w" sizes="(max-width: 512px) 100vw, 512px" /></figure>
<h2 class="wp-block-heading">Post-Election Animal Spirits</h2>
From election day through early February, risk assets surged. Equities rallied as markets priced in a pro-growth, pro-inflation policy mix: tax cuts, infrastructure spending, and deregulation.
That optimism drove bond yields sharply higher. The S&amp;P 500 gained in relation to TLT, as expectations for economic growth and inflation soared. It was during this period that the bond vigilantes returned. Bond investors, wary of unchecked fiscal expansion, began demanding higher yields on long-dated Treasuries. Some were calling for — and actively pricing in — 10-year yields above 5% — warning of a potential <a href="https://edition.cnn.com/2025/01/14/business/trump-market-debt">"Liz Truss moment" for the United States</a>.
<h2 class="wp-block-heading">10-Year Yield As The New North Star</h2>
In February, the tone began to shift. The administration appeared increasingly focused on managing optics around the 10-year yield. Social media narratives pivoted away from stock performance and toward long-end Treasury rates and government spending efficiency. 
Treasury Secretary Scott Bessent openly prioritized stabilizing the 10-year yield. He seemed comfortable with a slowdown in growth and even a market correction — if it meant restoring fiscal credibility. Notably, he described tariffs as a tool for deficit reduction by generating additional revenue.
This narrative shift culminated in the "Liberation Day" correction. Equities sold off sharply, driving a temporary flight to quality in Treasuries. Markets had moved from a pro-growth framework to one dominated by concerns over rising rates, tighter financial conditions, and a more restrictive fiscal stance.
<h2 class="wp-block-heading">A Policy U-Turn</h2>
Despite this, the bond market's triumph was short-lived. Shortly after "Liberation Day," markets began pricing in a recession — ironically, a scenario that is also negative for bonds. Recessions typically bring deficit expansions, which are problematic for long-term sovereign debt. With a deficit already near 7% of GDP in non-recessionary conditions, the risk of unsustainable debt dynamics loomed large.
Momentum shifted again. The administration postponed planned tariffs and soon unveiled the "Big, Beautiful Bill" — widely interpreted as a pivot back toward pro-growth policy. Equities rallied, and the S&amp;P 500/TLT ratio climbed higher once more. But this rebound in equity sentiment came at a cost: renewed concern about the long-term sustainability of U.S. fiscal policy and its impact on long-end yields.
<h2 class="wp-block-heading">No Room for Error</h2>
To keep the long end of the curve under control, the administration faces a perilously narrow policy corridor. In our view, the best possible outcome is a mild economic slowdown or shallow recession — enough to cool inflation expectations without triggering another surge in deficit spending.
That scenario could prompt a correction in the S&amp;P 500, driven by stagnant or negative EPS growth. If investors react negatively to the slowdown in earnings, a correction is likely. However, if markets look through the temporary dip in EPS — viewing it as a short-term issue that will improve in the following year — then a correction may not occur. On the other hand, overheating the economy could prove far worse. If policymakers lose control of the long end of the Treasury curve, the cost of capital could rise sharply, placing serious pressure on equity valuations.
The current uncertainty is likely to persist. Investors would do well to track the S&amp;P/TLT ratio closely. When the ratio climbs, it's likely a signal to reduce equity exposure and shift toward bonds. When the ratio falls, it may be a good time to add to equities, as they may be poised for recovery. Either way, this ratio offers a real-time lens on the underlying tension shaping markets in 2025.

Opinion

Signals

Stocks vs. Bonds: What The S&P 500/TLT Ratio Is Signaling Now

VCI Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) ("VCI Global" or the "Company"), today announced that its portfolio company, QuantGold Data Group Limited ("QuantGold"), acquires Secure Encryption Storage Limited ("SES") — a leading encryption hardware company with 129 patents and institutional deployments across over 100 organizations in Asia. With this acquisition, VCIG is positioned to enter the encryption infrastructure sector, anchoring both commercial expansion and sovereign technology development.
SES brings a track record of deployment across sensitive environments in Asia, including government agencies, telecom operators, leading financial institutions, aviation networks, and mobile device manufacturers. Its hardware is built on both symmetric and asymmetric cryptographic standards and designed for resilience against emerging quantum decryption threats. Select devices have achieved EAL4 certification, suitable for national cybersecurity use.
VCIG gains exclusive rights to distribute SES's full product suite in certain regions of Southeast Asia, targeting institutional and enterprise clients across sectors such as telecommunications, finance, and national infrastructure. The portfolio includes military-grade encrypted storage systems with real-time backup, encrypted GPUaaS and AIaaS services, secure mobile communication devices, and advanced field-ready data intelligence hardware. Several of these technologies are already in use by over 100 institutional clients across the region.
SES's encryption stack will become a core component of QuantGold's sovereign AI infrastructure—a platform enabling encrypted data processing across high-value sectors such as finance, healthcare, and critical infrastructure. By embedding encryption at the chip level, QuantGold ensures privacy-preserving compute, zero-trust architecture, and blockchain-based validation for regulatory compliance and cross-border protection.
The global cybersecurity market is projected to exceed US$425 billion by 2030, driven by the exponential rise in digital threats and regulatory mandates. Simultaneously, the AI data monetization sector is expected to surpass US$400 billion by 2035, fueled by enterprise adoption of AI models requiring secure, high-quality data access. Through this acquisition and platform integration, VCIG and QuantGold are strategically positioned to serve both megatrends—by delivering encryption at the hardware layer and monetization at the compute layer.

VCIG

VCI Global's Portfolio Co. QuantGold Data Group Acquires Secure Encryption Storage Limited; No Financial Terms Disclosed

Esperion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) today announced that it has entered into a settlement agreement with Accord Healthcare Inc. This agreement resolves the patent litigation brought by Esperion against Accord Healthcare Inc. in response to Accord Healthcare Inc's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Accord Healthcare Inc. has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.
The pending patent litigation against the remaining defendants (Alkem Laboratories Ltd.; Aurobindo Pharma Limited (along with an affiliate); Dr. Reddy's Laboratories Inc. (along with an affiliate); MSN Pharmaceuticals Inc. (along with an affiliate); Renata Limited; and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of NEXLETOL and/or NEXLIZET, as applicable, to be marketed in the U.S. prior to April 19, 2040.

Biotech

General

ESPR

Esperion Reaches Settlement With Accord Healthcare To Delay U.S. Launch Of Generic NEXLETOL Until At Least April 2040

Citigroup analyst Alexander Hacking reinstates Alcoa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) with a Buy and announces $42 price target.

Price Target

Initiation

Analyst Ratings

Citigroup Reinstates Buy on Alcoa, Announces $42 Price Target

BCTX

BCTX stock has given up its prior gain. BriaCell shares were trading higher after the company reported a 52% one-year survival rate in its Phase 2 metastatic breast cancer trial.

As Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) prepares to unveil its second-quarter <a href="https://www.benzinga.com/quote/LEVI/earnings">earnings on July 10</a>, the iconic denim brand finds itself at a pivotal moment, navigating both market challenges and strategic changes. This earnings report will not only provide insight into Levi&#8217;s financial health but also influence its appeal to dividend-seeking investors, as the company currently offers a competitive yield amid a fluctuating retail landscape.
Analysts expect the company to report quarterly earnings at 13 cents per share, down from 16 cents per share in the year-ago period. Levi Strauss projects to report quarterly revenue of $1.37 billion, compared to $1.44 billion in the same quarter a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 20, Levi Strauss entered into a definitive agreement to sell Dockers&#xAE; to Authentic Brands Group.
With the recent buzz around Levi Strauss, some investors may also be eyeing potential gains from the company's dividends. As of now, Levi Strauss offers an annual dividend yield of 2.81%, which is a quarterly dividend amount of 13 cents per share (52 cents a year).
To figure out how to earn $500 monthly from Levi Strauss, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Levi Strauss $0.52 dividend: $6,000 / $0.52 = 11,538 shares.
So, an investor would need to own approximately $225,568 worth of Levi Strauss, or 11,538 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $0.52 = 2,308 shares, or $45,121 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
LEVI Price Action: Shares of Levi Strauss gained by 2.3% to close at $19.55 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46271576/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-8">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo: Shutterstock

Earnings

Dividends

LEVI

How To Earn $500 A Month From Levi Strauss Stock Ahead Of Q2 Earnings

Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) with a Buy rating and announces Price Target of $30.

NVCR

Ladenburg Thalmann Initiates Coverage On NovoCure with Buy Rating, Announces Price Target of $30

BSGM

BigSig Technologies shares are trading higher after the company announced it generated $1.1 billion in financing to launch a gold-backed treasury strategy and RWA tokenization platform.

Loop Capital analyst Alton Stump downgrades Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) from Buy to Hold and maintains the price target from $127 to $127.

Downgrades

SHAK

Loop Capital Downgrades Shake Shack to Hold, Maintains Price Target to $127

Ten-League International Holdings Limited (the "Company" or "Ten-League"), a Singapore-based provider of turnkey project solutions, today announced the pricing of its initial public offering (the "Offering") of 2,240,000 ordinary shares, 1,607,840 of which are being offered by the Company and 632,160 by selling shareholders, at a public offering price of US$4.00 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on July 08, 2025 under the ticker symbol "TLIH."
The Company expects to receive aggregate gross proceeds of US$6,431,360 from the Offering, before deducting underwriting discounts and other related expenses. The Offering is expected to close on or about July 09, 2025, subject to the satisfaction of customary closing conditions.
Proceeds from the Offering will be used for: (i) expanding the Company's product offering; (ii) improving the Company's automation process and investing in equipment and technology; (iii) expanding through strategic targeted acquisitions and investments; (iv) marketing and brand building; (v) repayment of bank borrowing, and (vi) working capital and other general corporate purposes.
The Offering is being conducted on a firm commitment basis. Bancroft Capital, LLC is acting as the sole underwriter for the Offering.

IPOs

TLIH

Ten-League International Prices ~$6.43M IPO Of 2.24M Shares At A Price Of $4/Share

Guidance

Financing

PGNY

Progyny Enters Revolving Credit Facility Up To $200M; Co. Also Says Second Quarter Results Anticipated To Be Slightly Above Previously Provided Financial Guidance

Barclays analyst Adrienne Yih upgrades National Vision Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) from Equal-Weight to Overweight and raises the price target from $17 to $30.

Upgrades

Barclays Upgrades National Vision Holdings to Overweight, Raises Price Target to $30

The project will help transition local industries to 100% renewable base-load energy and connect remote communities to diversified energy sources

AMRC

Ameresco Partners With Juneau Hydropower For $240M Hydropower Project

Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) ("we," the "Company" or "Nano Labs"), a leading Web 3.0 infrastructure and product solution provider in China, today announced a strategic partnership with Layer 2 cross-chain bridge protocol Orbiter Finance to jointly develop a compliant stablecoin distribution and exchange service across multiple networks. The service will support various compliant stablecoins, including those pegged to USD, HKD, offshore RMB.
Leveraging Orbiter Finance's multi-chain support capabilities alongside Nano Labs' expertise in Web3.0, the new solution aims to provide users with low-cost, compliant cross-chain transfers and mainstream token exchanges. The initial product is expected to launch in Q4 2025, with the tentative domain name NBNB.io.
Built on a secure and efficient cross-chain infrastructure for stablecoins, this collaboration is designed to promote the widespread adoption of compliant stablecoins across both DeFi and traditional finance sectors.
Looking ahead, both parties plan to expand support for additional blockchains and drive adoption in institutional-grade applications.

Nano Labs Partners With Orbiter Finance To Launch Compliant Multi-Chain Stablecoin Exchange By Q4 2025

WeightWatchers shares are trading higher after the company announced it has completed a strategic reorganization, including senior leadership changes, a strategic expansion, and relisting on Nasdaq.

SRXH

SRX Health shares are trading higher after the company announced the closing of a $7.3 million convertible note financing.

SeaStar Medical Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that the QUELIMMUNE therapy has been adopted for use by the nationally recognized Texas Children's Hospital. The QUELIMMUNE therapy was approved by the U.S. Food and Drug Administration (FDA) in 2024 under a Humanitarian Device Exemption application for pediatric patients with AKI due to sepsis or a septic condition on antibiotic therapy and requiring Renal Replacement Therapy (RRT). Clinical data from the FDA application and subsequently published in <a href="https://www.globenewswire.com/Tracker?data=0KO2DbUqT2tKG7aJdk7ZACoXpjUSaocsgZgE0Iy9ZIhZXFxI2KBoUBUvq6zN73Dg2I6kP0BjJfMtf3HEzq70CnrstX3OobEm58jwznmRCQLepXm92gbBajpaqcELyhnvpX9aVjC12MfXp1ZwuhF9XCj1GqCmkKDAK-zEK7Bv3co=">Kidney Medicine</a> showed a 77% survival rate in patient treated with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data in this patient population. No dialysis was required for survivors at Day 60 after ICU discharge.

SeaStar Medical Holding Says QUELIMMUNE Therapy Adopted For Use By Nationally Recognized Texas Children's Hospital

La Rosa Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) ("La Rosa" or the "Company"), a real estate and PropTech company, today announced a strategic agreement between its wholly owned subsidiary, La Rosa Realty LLC ("La Rosa Realty"), and The Agency Dominican Republic ("TADR"), securing rights for its agents to act as co-brokers to market and sell units of the IBIS Romana Bayahibe ("IBIS") project in Dominican Republic, and exclusive rights for any sales of IBIS in Puerto Rico.
Located in Bayahibe, La Romana, Dominican Republic, IBIS is a luxury residential and resort-style real estate development company. The development features premium resort-style residences and world-class amenities. As part of the agreement, La Rosa will participate in sales of IBIS in Dominican Republic and serve as the exclusive sales agent for any sales of IBIS in Puerto Rico. In connection with this agreement, La Rosa intends to provide targeted sales strategies to a high-potential Latin American and Caribbean buyer base.
Key Benefits of the Agreement:
<ul>
<li>360-Day Protected Client Registration:&nbsp;Agents within the La Rosa network can register clients and secure commissions on international sales in Dominican Republic and Puerto Rico for an entire year per registration.</li>
<li>Fast-Tracked Client Onboarding:&nbsp;The agreement includes a 24-hour turnaround on client confirmation from TADR, expediting deal flow and enhancing agent efficiency.</li>
<li>Recurring Revenue Potential:&nbsp;With new luxury IBIS projects underway and commissions paid per transaction, La Rosa expects that going forward this cooperation will add a recurring, scalable revenue stream tied to international real estate sales in Dominican Republic and Puerto Rico.</li>
<li>Exclusive Territory Rights:&nbsp;La Rosa secures sole sales rights in Puerto Rico for any sales of, positioning the company as the bridge between Dominican Republic developers and Puerto Rican investors.</li>
</ul>

LRHC

La Rosa Secures Exclusive Puerto Rico Sales Rights For Dominican Luxury Real Estate Project In Deal With The Agency Dominican Republic

Press Releases

Ascent Industries Co. Announces Sale of Bristol Metals, LLC for $45 Million

Ascent Industries Brings Performance-Driven Oil & Gas Solutions to AFPM 2025

Ascent Industries Co. Announces Successful Completion of Sale of Bristol Metals, LLC

Ascent Industries Co. Announces Multi-Year Specialty Chemicals Contract, Driving Significant EBITDA Growth

Ascent Industries Announces Upcoming Investor Conference Schedule

Ascent Industries Sets First Quarter 2025 Earnings Conference Call for May 12, 2025, at 5:00 p.m. ET

Ascent Industries Reports First Quarter 2025 Results

Ascent Industries Co. to Divest American Stainless Tubing for $16 Million, Marking Final Step in Strategic Portfolio Realignment

Ascent Industries' Transformation Recognized with Russell 2000 Index Inclusion

Ascent Industries Co. Completes Sale of American Stainless Tubing, Finalizing Transformation to Pure-Play Specialty Chemicals Platform

Alpha Metallurgical Resources, Inc. Common Stock

Alpha Metallurgical

Cleveland-Cliffs

Commercial Metals

Carpenter Technology Corporation Common Stock

Carpenter Tech

Friedman Indus

Gerdau

Warrior Met Coal

Luda Technology Group Limited Ordinary Shares

Luda Technology Group

Ramaco Resources, Inc. - Class A Common Stock

Ramaco Resources

Ramaco Resources, Inc. - Class B Common Stock

Mesabi Tr

ArcelorMittal

Metallus

Nucor

POSCO HOLDINGS INC. American Depositary Shares (Each representing 1/4th of a share of Common Stock)

POSCO Holdings

Radius Recycling, Inc. - Class A Common Stock

Radius Recycling

Reliance

Ryerson Holding

Companhia Siderurgica Nacional S.A. Common Stock

Companhia Siderurgica

Steel Dynamics

SunCoke Energy

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares, USD1.00 par value)

Comments

Ascent Industries

Notizie

Ultime notizie per Ascent Industries (NASDAQ:ACNT) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO